ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|

Trending News

The END ME/CFS Project

The CFS/ME Brain Is Inflamed

SURVEY: Cognitive Impairment

Disability Claims and Social Media

Ask the Doctor: What Are Your Favorite Treatments for ME/CFS?

High-Throughput Sequencing of Plasma MicroRNA in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Epigenetics & immune dysfunction in ME/CFS

“End ME/CFS” Mega Chronic Fatigue Syndrome Project Begins

Use of single-nucleotide polymorphisms (SNPs) to distinguish gene expression subtypes of chronic fat...

Inflammatory and oxidative and nitrosative stress cascades as new drug targets in myalgic encephalom...

 
Print Page
Email Article

Newcastle Group Implements New Diagnostic Tool for ME/CFS

  [ 1 vote ]   [ Discuss This Article ]
www.ProHealth.com • February 28, 2013


Editor's Comment: The CDC, or “Fukuda,” case definition for CFS has been criticized for inaccuracy. The Canadian Case Definition, which is accurate, but lengthy, was revised in 2010 to make it more accessible to clinicians. The questionnaire referred to in this article is based on the revised Canadian Criteria. These, while comprehensive, contain an exclusion of “any active medical condition that may explain the presence of chronic fatigue.” Those who do not consider fatigue but post-exertional malaise as the primary symptom of ME/CFS find this phrase objectionable.

Press Release: Evaluating the DePaul Symptom Questionnaire in the ME Research UK cohort: extension study

Investigator: Prof. Julia Newton

Institution: Institute for Ageing and Health, The Medical School, Newcastle University, Newcastle upon Tyne, UK

Funding: Funding for this study has been provided by ME Research UK

Background and Aim

Since 2006, the group at Newcastle University has received several grants from ME Research UK. The largest of these (£130,000), awarded in conjunction with the John Richardson Research Group and the Irish ME Trust in 2007, was to investigate autonomic nervous system parameters along with muscle, liver and heart function in a large patient cohort. A series of novel scientific papers has emanated from this programme of work, and the researchers have reported that, compared with healthy people, many ME/CFS patients have a) impaired cardiac function, including reduced cardiac mass and blood pool volumes; b) dysfunction of the autonomic nervous system; c) fatigue that is directly related to the burden of autonomic nervous system symptoms; d) an abnormal heart rate response to standing; e) a lower blood pressure, and abnormal blood pressure regulation; and f) substantially slower recovery from standardised exercise of the skeletal muscles.). In the context of ME/CFS, these findings have had an important impact, most particularly in pointing up key areas of importance for diagnosis – a particularly useful outcome given the difficulties of diagnosis faced by patients and clinicians.

At present there are several case definitions for ME/CFS, however, but all are exclusionary and rely on collections of non-specific symptoms shared with other illnesses. For example, the most widely used case definition is the Fukuda (1994) criteria which uses polythetic criteria (i.e., patients are only required to have 4 out of a possible 8 symptoms), but 2 of these 8 symptoms (post-exertional malaise and memory/concentration problems) are thought to be an essential feature of the illness and the Fukuda criteria do not require that these symptoms be present among all patients.

Significant methodological problems could occur if investigators in different settings recruit samples with different percentages of these core symptoms. By contrast, the Canadian clinical case definition (2003) requires specific ME/CFS symptoms such as post-exertional malaise and memory/concentration problems to be present, but this case definition tends to be more complex to apply and has been used relatively rarely for diagnosis or research purposes compared with the more widely used Fukuda definition. Importantly, neither of these definitions has been formally operationalised.

Prof. Leonard Jason at DePaul University, Chicago has been in the forefront of research into the development and application of diagnostic criteria for ME/CFS for more than a decade. In 2010, he developed a standard questionnaire (The DePaul Symptom Questionnaire, DSQ) to assess core symptoms of ME/CFS, with the aim of ensuring that symptoms are assessed in a consistent way across settings to aid in diagnosis.

This questionnaire has now been refined (Jason et al, American Journal of Biochemistry and Biotechnology) and is being made available to other research groups for operational testing on existing ME/CFS cohorts. Importantly, the DSQ now comes in a format which scores symptoms and SF36 data, and produces a “diagnosis” based on several of the more common definitions of ME, CFS and ME/CFS. If this instrument is found to be sufficiently sensitive, it could greatly assist patient diagnosis, saving time (as it can be completed in the patient’s home and brought to the clinic for scoring) and improving confidence in the diagnosis.

In the course of the ME Research UK-funded patient cohort study at Newcastle University, the researchers have collected a large volume of clinical, autonomic and symptom data, and they have available full data sets from almost 200 patients who have attended the Newcastle ME/CFS Service and been referred to their research programme. Each of these patients has been assessed on the basis of the Fukuda 1994 CFS and the Canadian 2003 ME/CFS definitions as part of their clinical examinations, but through the timely development of the DSQ an opportunity has arisen to compare the clinical diagnoses of patients in the Newcastle ME Research UK cohort with those derived from the more structured DSQ instrument. The results obtained will also be shared with Prof. Jason’s group in Chicago, adding to the data on the usefulness of the DSQ which he hopes to acquire from research groups around the world in different populations of patients. Considering the importance of the ME Research UK cohort and its well-characterised nature, the results could throw valuable light on diagnostic categories and on the utility of the DSQ in practice.

Source: ME Research 



Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Vitamins and Supplements

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 your brain needs for detox & sharpness
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
MitoQ® MitoQ®
Powerful Antioxidant Support to Mitochondria
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Undenatured Type II Collagen - Chicken Soup for Your Joints Undenatured Type II Collagen - Chicken Soup for Your Joints
Repair Damaged Mitochondria and Reduce Fatigue Up to 45% Repair Damaged Mitochondria and Reduce Fatigue Up to 45%
Are You Obtaining the Proper Enzymes? Are You Obtaining the Proper Enzymes?
Rejuvenating the Brain - How PQQ Helps Power Up Mental Processing Rejuvenating the Brain - How PQQ Helps Power Up Mental Processing
Shoo Pain, Don't Bother Me - Top 10 Nutrients to Take Back Your Life Shoo Pain, Don't Bother Me - Top 10 Nutrients to Take Back Your Life

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing